GeneReach Biotechnology Corp. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 106.65 million compared to TWD 283.16 million a year ago. Revenue was TWD 105.82 million compared to TWD 282.29 million a year ago. Net income was TWD 36.92 million compared to TWD 110.18 million a year ago. Basic earnings per share from continuing operations was TWD 0.64 compared to TWD 1.92 a year ago. Diluted earnings per share from continuing operations was TWD 0.64 compared to TWD 1.872 a year ago.
For the nine months, sales was TWD 665.81 million compared to TWD 793.51 million a year ago. Revenue was TWD 664.75 million compared to TWD 790.42 million a year ago. Net income was TWD 273.9 million compared to TWD 312.96 million a year ago. Basic earnings per share from continuing operations was TWD 4.768 compared to TWD 5.448 a year ago. Diluted earnings per share from continuing operations was TWD 4.6 compared to TWD 5.384 a year ago.